TetraLogic Reports Initiation of Randomized Phase 2 Trial of SHAPE for Cutaneous T-Cell Lymphoma

By: via Benzinga
TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.